Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261502 | SCV002541244 | uncertain significance | not provided | 2021-05-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003348823 | SCV004068163 | uncertain significance | Inborn genetic diseases | 2023-07-19 | criteria provided, single submitter | clinical testing | The c.1375G>A (p.E459K) alteration is located in exon 10 (coding exon 10) of the SLC12A6 gene. This alteration results from a G to A substitution at nucleotide position 1375, causing the glutamic acid (E) at amino acid position 459 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003408188 | SCV004109832 | uncertain significance | SLC12A6-related disorder | 2023-07-27 | criteria provided, single submitter | clinical testing | The SLC12A6 c.1375G>A variant is predicted to result in the amino acid substitution p.Glu459Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-34543217-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |